ライフサイエンスコーパス: treated with

1 rular filtration rate >=25 to <75 mL per min per 1.73 m(2), treated with optimized renin-angiotensin system blockade.

2 icroscopic studies performed in mice fed with cuprizone and treated with anacardic acid showed lower g-ratio scores when

3 roups included patients who were removed from the study and treated with topical corticosteroids according to best medica

4 patients, including those with SPINK1-positive subtype, are treated with AR-antagonists.

5 er, cases of Junin virus infection, a related virus, can be treated with convalescent-phase serum.

6 Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but

7 ase and moderate or severe ischemia on stress testing to be treated with an initial invasive strategy consisting of coron

8 ound no significant difference in 28-day survival for cases treated with IVF (27.3%) compared to those not treated with I

9 NF2-null cells treated with an ERBB3-neutralizing antibody partially downreg

10 first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromb

11 Jude Lifetime Cohort treated with cyclophosphamide equivalent dose (CED) >=4,000 m

12 re dysregulated more in physiologically relevant conditions treated with AZM, likely due to general changes in cell physi

13 with stage II to IV DAWT compared with historical controls treated with regimen I.

14 C57BL/6J female mice (n = 18) were first treated with antibiotics for 4 weeks to ablate the microbiota

15 Primary care patients with influenza-like illness treated with oseltamivir recovered one day sooner on average

16 ngly relevant for patients with haematological malignancies treated with chronically administered therapies.

17 Mice treated with PLX5622 had a significantly faster decrease of t

18 in a puromycin aminonucleoside (PAN) nephropathy rat model treated with amiloride, an inhibitor of plasminogen activatio

19 A subset analysis of vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1) agen

20 al for cases treated with IVF (27.3%) compared to those not treated with IVF (26.9%) during their entire ETU admission (P

21 Patients treated with intra-arrest transport (exposed) were matched wi

22 In phase 2, patients treated with combination therapy achieved an overall response

23 a higher incidence of aspirin resistance than all patients treated with aspirin alone and TCT decreased the frequency of

24 were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES.

25 In pseudophakic RRDs, SSAS was better in patients treated with PPV-SB compared with PPV alone, whereas visual o

26 on has been proposed as a potential risk factor in patients treated with RAAS inhibitors.

27 ctomy leads to better disease-specific survival in patients treated with surgery alone.

28 After up to 6 years of follow-up, patients treated with mite allergoid required significantly fewer AR a

29 ents with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansi

30 NA from chondrocytes harvested from knees of rats with PTOA treated with liposomal A2AR agonist revealed downregulation o

31 e to those in the intravascular space was increased in rats treated with rTM although the statistical power for this was

32 arable pseudophakic rhegmatogenous retinal detachment (RRD) treated with pars plana vitrectomy (PPV) or PPV with scleral

33 Among the 49 survivors treated with ECMO, 32 who had been treated at the largest cen

34 uropean ancestry, including 34 nonirradiated male survivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 2

35 ED < 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 24 male survivors treated with CED >=4,000 mg/m(2) and radiotherapy <40 Gray (P

36 Group 2 (n=30) were treated with the same schedule and had sparse dolutegravir ph

37 antibody [CDC PRA+], C1q+) heart transplant candidates were treated with the combination of belatacept and PI therapy, wh

38 Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 rece

39 or after establishment of autoimmune myocarditis, mice were treated with the immunoproteasome inhibitor ONX 0914.

40 Transplanted mice were treated with vehicle or di-n-butyl-phthalate (DBP, a plastici

41 All patients were treated with biguanides and/or diamidines or azoles without r

42 All patients were treated with definitive chemoradiation (median dose 50.4 Gy)

43 All patients were treated with gemcitabine and S-1 (GS)-based chemotherapies wi

44 tic, hypertensive heart failure rat (mRen27/tetO-shIR) were treated with empagliflozin (10 mg/kg/d) or vehicle for 4 week

45 Most patients with SMPE were treated with embolectomy (98.9% [91 of 92]), while ECMO was u

46 Spheroids were treated with 5-Fluorouracil for five days through continuous

47 o patients from 7 medical centers in the United States were treated with axi-cel and were included in a modified intent-t

48 Twenty-seven patients with low CrAg titers were treated with antifungal therapy and 22 (81%) responded well c

49 with histologically confirmed stage IIIB-IV NSCLC who were treated with immune checkpoint blockade between June 2011 and

50 B-cell acute lymphocytic leukaemia have poor outcomes when treated with regimens that do not contain a tyrosine-kinase i